# The association between body mass index and metabolite response to a liquid mixed meal challenge.

### **Authors**

David A. Hughes<sup>1,2</sup>, Ruifang Li-Gao<sup>3</sup>, Caroline J. Bull<sup>1,2</sup>, Renée de Mutsert<sup>3</sup>, Frits R.
 Rosendaal<sup>3</sup>, Dennis O. Mook-Kanamori<sup>3,4</sup>, Ko Willems van Dijk<sup>5,6</sup>, Nicholas J. Timpson<sup>1,2.</sup>

### Affiliations

- 9 <sup>1</sup> MRC Integrative Epidemiology Unit at the University of Bristol, UK
  - <sup>2</sup> Population Health Science, Bristol Medical School, University of Bristol, UK
    - <sup>3</sup> Department of Clinical Epidemiology, Leiden University Medical Center, Leiden, the
- Netherlands
   <sup>4</sup> Department of Public Health and Primary Care, Leiden University Medical Center, Leiden, the Netherlands
- <sup>5</sup> Department of Human Genetics, Leiden University Medical Center, Leiden, the Netherlands <sup>6</sup> Department of Internal Medicine, Division of Endocrinology, Leiden University Medical Center, Leiden, the Netherlands

18

3

## **Keywords**

BMI, metabolomics, metabolite, Mendelian Randomization, MR, meal challenge, response,

21 NEO

### Abstract

#### 18 Background

Metabolite abundance is a dynamic trait that is not only variable in a fasting state, but also varies in response to environmental stimuli, such as food consumption. Postprandial

- 21 abundance and response to a meal are emergent traits in studies of disease and which themselves may be subject to specific risk factors. We investigated body mass index (BMI) as a recognized risk factor for numerous health outcomes that may influence metabolite response
- 24 to feeding. Here we use the Netherlands Epidemiology of Obesity (NEO) study to examine associations between BMI and metabolite response to a liquid meal and extend this by using Mendelian randomization (MR) to estimate potential causal effects.

#### 27 Methods and findings

The NEO study conducted a liquid meal challenge and collected metabolite profiles using the Nightingale metabolomics platform in 5744 study participants. Observational and one-sample

- 30 MR analysis were conducted to estimate the effect of BMI on metabolites and ratios of metabolites (n = 229) in the fasting, postprandial and response (or change in abundance) states. After an appropriate multiple testing correction, we observed 473 associations with
- 33 BMI (175 fasting, 188 postprandial, 110 response) in observational analyses. In MR analyses, we observed 20 metabolite traits (5 fasting, 12 postprandial, 3 response) to be associated with BMI. In both the fasting and postprandial state, this included citrate and the ratios of linoleic
- 36 acid, omega-6 fatty acid and polyunsaturated fatty acids to total fatty acids. In addition, the glucogenic amino acid alanine was inversely associated with BMI in the response state, suggesting that as alanine increased in postprandial abundance, that increase was attenuated
- 39 with increasing BMI.

#### Conclusions

Overall, MR estimates were strongly correlated with observational effect estimates suggesting

- 42 that the broad associations seen between BMI and metabolite variation in fasting, postprandial and response states have a causal underpinning. Specific effects in previously unassessed postprandial and response states were detected and these may likely mark novel life course
- 45 risk exposures driven by regular nutrition.

### 48 Introduction

The excess accumulation of body fat and obesity are an established global health burden, the 51 prevalence of which is increasing. The incidence and cost in life and dollars was estimated to be 1.9 billion cases in 2016, 4 million attributed deaths in 2015 and two trillion US dollars in 2014, respectively (1–3). Body mass index (BMI), or the ratio of one's weight and height

- 54 squared (kg/m<sup>2</sup>), is a common metric for measuring excess weight or fat and BMI thresholds of greater than or equal to a value of 25 and 30 are used to designate the conditions of overweight and obesity, respectively (4,5). While the use of BMI as an obesity metric – one
- 57 that varies with age, sex, and ethnicity/genetic ancestry may underestimate the true global burden of excess body fat, it has been an important and easily derived anthropometric and diagnostic metric in the study of obesity (6–9). Increases in BMI have been associated with
- 60 decreased life expectancy (10–13), some cancers (14–16) and with cardiometabolic diseases including cardiovascular disease, and type 2 diabetes (17).
- 63 Despite the scale of the BMI related health burden, there remains a need to elucidate how and by what intermediate physiological traits excess body fat increases disease risk. Possible intermediates are metabolites and lipoproteins, some of which – like low density lipoprotein
- 66 (LDL) or its' crucial protein apolipoprotein B have been previously associated with both BMI and disease risk (18–26). In a recall-by-genotype framework, previous work supports a causal role of body mass index on metabolite variation (27,28). Other work demonstrated a
- 69 broad observational and consistent causal association between BMI and metabolites or specifically lipoprotein subclasses, branch-chain amino acids, and inflammatory markers in a young adult cohort (18).
- 72

In 1950, John Moreton illustrated the presence of intra-individual variability in chylomicrons after a high fat food (cream) challenge (29). More recent work has illustrated additional

- 75 metabolite variation postprandially that could prove informative in evaluating disease risk and informing precision medicine (30–35). Yet, Schutte et al, building on the work of others (18), has illustrated that observational effect estimates between BMI and metabolite abundances are
- 78 strongly, but not uniformly, consistent between fasted and postprandial metabolite abundance measurements (36). This observation suggests that for some metabolites fasting versus postprandial status may not be critically important for meta-analyses that aim to estimate the

- 81 association between BMI and metabolite abundance. It also suggests that for other metabolites there is novelty in postprandial measurements and their association with BMI.
- 84 In this context and with most individuals spending much of their waking hours in a non-fasted or postprandial state, it is important to understand both the variation in postprandial metabolite abundance and the association and influence BMI may have on dynamic ranges in
- 87 metabolomic response. Similar to an oral glucose tolerance test (OGTT), whose postprandial abundance is informative about an individuals' insulin sensitivity and diabetic state, postprandial metabolite abundances may prove informative in the study of disease traits (37).
- 90 Consequently, a comprehensive assessment of postprandial variation and response is essential in the study of adiposity, metabolites, and disease.
- 93 Response, defined as the change in metabolite abundance between fasted and postprandial states, has received little to no attention in disease risk research. In contrast to fasting status, response can be assessed either through a basic measurement of postprandial metabolite
- 96 profile after a standardized feed (assuming that baseline variability is essentially random in a large enough sample), or through the explicitly modelling of response accounting appropriately for pre-feed variation. Either way, there is evidence that this dynamic state is
- 99 different and potentially informative versus classically measured fasting levels. For example, a recent genome-wide association analysis identified genetic variants uniquely associated with metabolite response traits that did not share associations with fasting or postprandial
- 102 abundances (38). Moreover, estimates of genotype heritability for some response traits such as the (branched-chain) amino acids, glucose and extremely large VLDL are as large or larger than those observed for fasting and postprandial estimates. Taken together, results suggest that
- 105 such state specific traits are likely to be qualitatively different and may prove informative in explaining the aetiology of disease.
- 108 Currently missing from the literature are studies explicitly assessing the potentially causal relationship between variation in the commonly recognized risk factor BMI and the dynamic response of the metabolome to feeding. This is potentially difficult to examine given the
- 111 strongly confounded nature of BMI as a risk factor, however Mendelian randomization (MR) is a framework using instrumental variable (IV) analysis to deploy genetic variants as exposure proxies in efforts to obtain evidence of causal relationships (39,40). It has been
- 114 increasingly possible to exploit an increasing collection of confirmed genetic associations

with BMI for the purpose of estimating likely downstream consequences in variation (41–49) and aggregate genetic scores have become useful in their capacity to capture heritable

117 variance in exposures of interest (like BMI) despite potential complexities (50). There is, therefore, an opportunity to apply this approach to the examination of potential relationships between BMI and metabolite profiles.

120

We aimed to bring together data measuring the metabolic response to a liquid mixed meal and measures of the exposure, BMI, in observational and MR frameworks. These analyses,

- 123 undertaken in the Netherlands Epidemiology of Obesity (NEO) study, sought to estimate relationships between variation in BMI and metabolite abundance in both a fasted and postprandial states, and to assess metabolite response – or change in abundance between a
- 126 fasted and postprandial states.

#### Materials and Methods

#### **Study Sample**

- 129 The sample population was 6,671 participants of The Netherlands Epidemiology of Obesity (NEO) study, a prospective cohort study (51). The NEO study was conducted at the Leiden University Medical Center (LUMC) and approved by the LUMC Medical Ethical Committee.
- 132 All participants gave written informed consent.

The NEO sample population is derived from two populations. First, all individuals between

- 135 the ages of 45 and 65 years, living in the greater Leiden area, with a self-reported BMI of 27 kg/m<sup>2</sup> or higher. Second, all individuals in the municipality of Leiderdorp of the same age range, regardless of BMI (S1 Fig.). We will refer to these two sample populations as Leiden
- 138 and Leiderdorp respectively, and the entire study sample as NEO. Here our study sample population has a size of 5,744 defined by those participants who have genotype data, metabolite data, and other phenotype or covariable data available. Further details of the NEO
- 141 study and study design are previously published (52).

#### **Meal challenge**

An overnight fast was requested of all participants who subsequently visited the LUMC NEO study center and given a food challenge (38). During the visit an initial baseline, fasted blood sample was drawn. Second, within 5 minutes of the initial blood draw participants were given

- a liquid mixed meal. The meal was 400mL in volume with 600 kcal of energy. Sixteen
  percent of that energy (En%) was derived from protein, 50 En% from carbohydrates, and 34
- 147 percent of that energy (En%) was derived from protein, 50 En% from carbohydrates, and 34 En% was from fat. Third, following completion of the food challenge a blood sample was drawn at 30 minutes and again at 150 minutes. The NEO meal challenge occurred between the
- 150 months of September 2008 and September 2012, with participants from Leiden sampled throughout this period of time. Those participants from Leiderdorp were sampled, nonexclusively, during the months of June 2011 and September 2012.
- 153

The meal challenge sampling of Leiderdorp and Leiden population participants was structured by sampling date and as a product BMI was structured by sampling date. Specifically, BMI

156 was associated with the date of measurement (univariable linear model F-test p-value =  $4.7 \times 10^{-229}$ ), explaining 20.3% of the total variation in BMI (S2 Fig.). Despite this, the BMI-PGS had a smaller proportion (2.0%) of its variation explained by sampling date (univariate

159 linear model F-test p-value =  $3.9 \times 10^{-7}$ ). As a product of this structure, sampling date is included as a covariate in all observational and MR analyses.

#### **Metabolite data**

- 162 NEO participants had plasma derived metabolite profiles measured using the Nightingale Health (Helsinki, Finland) <sup>1</sup>H nuclear magnetic resonance (NMR) platform (53). For each participant both their fasting and 150 minutes postprandial samples were assayed. We note
- 165 here that metabolites are commonly defined as biological molecules less than 1.5 kilodaltons in size and that many of the molecules (lipids) assayed here are larger than this threshold. For simplicity we will refer to them all here as metabolites. At the time of sampling this
- 168 metabolomics platform provided 229 measurements for 149 metabolites including 80 derived ratio measurements (Table S1 in S1 File) from 14 substance classes: amino acids (n=8), apolipoproteins (n=3), cholesterol (n=9), fatty acids (n=11), fatty acids ratios (n=8), fluid
- balance (n=2), glycerides and phospholipids (n=9), glycerides and phospholipid ratios (n=2), glycolysis related metabolites (n=3), inflammation (n=1), ketone bodies (n=2), lipoprotein particle size (n=3), lipoprotein subclasses (n=98), lipoprotein subclass ratios (n=70).

#### 174 Data quality control

Prior to data analysis, metabolites and covariable quality control and data filtering steps were implemented. First, a single individual who self-described themselves as "other" rather than

- 177 "white" was excluded from the analysis. Second, any non-metabolite covariable with less than 1000 observations (n=1), with no variation (n=1), or binary covariables with fewer than 10 observations in either of the two binary classes (n=1) were removed. A complete list of
- 180 evaluated non-metabolite covariables is available in Table S2 in S1 File.

The initial metabolite data set consisted of 5,744 individuals, 229 fasting metabolites, 229 postprandial metabolites, and 148 previously derived (38) orthogonal nonlinear least squares

- 183 postprandial metabolites, and 148 previously derived (38) orthogonal nonlinear least squares (ornls) response metabolite traits. Data quality control of this data set was performed with the R package *metaboprep* (54). A complete description of the procedure and parameters used
- 186 with *metaboprep* can be found in S1 Text. After data QC 226 samples and 3 metabolites (all ornls response traits) were filtered from the data set (S1 Log). The log file (S1 Log) and report (S1 Report) generated by *metaboprep* are provided. After running *metaboprep* we also
- 189 performed the following steps on the fasted and postprandial data. First, all zero values were converted into NAs. Second, for each metabolite (in the fasting and postprandial state, individually) all values 10 interquartile distances from the median were also turned into NAs.

- 192 Third, we used the expected correlated nature of the fasting and postprandial data to identify outliers of that relationship, and turned them into NAs, in both dietary states. Further details on this procedure can be found in **S1 Text** and pre- and post-QC scatter plots for each
- 195 metabolite can be found in **S2 File**.

#### **Response trait**

A response trait, or a measure of change between the postprandial and fasting dietary state,
was derived for each of the 229 metabolites traits by univariable Deming regression. A
Deming regression was used here as it allows for error in both independent (fasting) and
dependent (postprandial) variables of the model and as such is a type of total least squares

- 201 regression. Following the QC steps described above we fit a Deming regression of postprandial on fasting data, for each metabolite. After model fitting the residuals were extracted and used as the response trait. The function deming() from the deming (v1.4) R
- 204 package was used in the analysis. The intercept and slope of Deming regression were recorded and are provided in Table S1 in S1 File, along with trait annotations and population summary statistics for all metabolite traits.

207

The residuals of the Deming regressions derived here were used as metabolite traits of response. These response traits effectively mirror those of a simple delta, in that positive

- 210 values indicate an increase in metabolite abundance in the postprandial state and negative values would indicate a decrease. Effect estimates from an association analysis with BMI, described below, therefore suggests whether response is associated with BMI. Positive effect
- 213 estimates suggest that as BMI increases, so too does the change in metabolite abundance. Negative effect estimates suggest that as BMI increases the change in metabolite abundance decreases.
- 216

Deming regressions residuals were taken to be the most appropriate way to summarize response for second stage analyses - observational and MR. However, in addition to the

- 219 Deming regression, we also used two alternative methods to derive response. The first was a simple delta estimate (postprandial minus fasting abundance) and the second was an orthogonal nonlinear least squares (ornls) regression. We note that simple delta values and
- 222 Deming residuals correlate with a mean Pearson's r of 0.94 (95% CI 0.65-0.99). The ornls response traits were derived and used previously in a genome wide association study of metabolite response and was used in our metabolite quality control steps described above

(38). Our result and discussion will focus exclusively on the Deming response traits, but all effect estimates for the delta and ornls response traits are provided in S3 File.

#### **Effective number of tested metabolites**

- 228 Whilst there are 687 metabolite traits (fasting = 229, postprandial = 229, response = 229) these are not independent (**S3 Fig.**). We used the R package *iPVs* (https://github.com/hughesevoanth/iPVs) to estimate the effective number of metabolites in
- 231 the data set (55–57). This allows us to ensure that we are not over correcting for the number tests we are performing in the study. We estimated 43 representative variables in the NEO metabolite data set. The data reduced, study-wide Bonferroni (BF) corrected p-value was set
- 234 to 0.05/43 or 1.163x10<sup>-3</sup>. A full description of the iPVs procedure and parameters can be found in S1 Text.

#### **Metabolite data description**

- 237 Two analyses were carried out to describe this Nightingale Health metabolomics data set. First, given the abundance of lipoproteins and their lipids in this data set we estimated the mean abundance of each lipid for each lipoprotein in both the fasting and postprandial dietary
- 240 states. Second, a paired Student's t-test was performed to determine if mean abundances differed between the fasting and postprandial states. Our threshold for declaring a change in mean abundance was 0.05/229, where 229 is the number of metabolites tested. We also
- 243 estimated the change as a delta value between the postprandial and fasting states and then derived estimates for average change and the 95% confidence interval of the change distribution.

#### 246 Rank normal transformation of metabolite traits

Each metabolite trait distribution was tested for normality with a Shapiro-Wilk test. All Wstatistics (untransformed distributions and model residuals) are reported in **S3 File**. In total

- 249 55.56% of all metabolite traits had a W-statistics less than 0.95, a threshold used here to define an inconsistency with normality. A total of 43.94% of all log-transformed metabolite traits had a W-statistics less than 0.95. Consequently, for the purpose of signal discovery and
- to allow for parametric analysis, each metabolite was rank normal transformed (tied values randomly ranked), prior to linear modelling. These steps resulted in the residuals from all observational and MR models to have a W-statistic greater than 0.9 and 0.99, respectively.

#### **Covariables**

Variables from 14 categories were compiled and available to identify possible confounders by

- 258 evaluating associations with BMI, BMI polygenic score (BMI-PGS), and metabolite traits (Table S2 in S1 File). These 14 categories are: anthropomorphic (n = 8), education (n = 5), income (n = 2), smoking (n = 3), diet including alcohol intake in grams (n = 24), medication
- 261 including glucose and lipid lowering (n = 10), systolic and diastolic blood pressure (n = 2), health including diabetes, glucose, hypertension and cancer status (n = 4), physical exercise (n = 18), basal metabolic rate (n = 1), indirect calorimetry (n = 5), genotype principal
- 264 components (n = 4). In addition, seven metrics of biological sample quality (n = 7) and the sampling information (visit date and sub-population, n = 2) were included in the study to assess influence on metabolites. During quality control, described above, 3 variables were
- 267 filtered. As performed with metabolites above we estimated the effect number of covariables in the data set. After running an iPVs analysis with a tree cut height of 0.5 we estimated that there are 54 representative or independent covariables. As a product any test performed across
- 270 all covariables was corrected for multiple testing at a p-value of 0.05/54 or  $9.29 \times 10^{-4}$ .

#### **Genotype data**

The NEO participants were genotyped on the Illumina HumanCoreExome-24 BeadChip

273 (Illumina Inc., San Diego, California, United States of America), at the Centre National de Génotypage (Evry Cedex, France). Following genotype quality control steps, as previously described (58), sample were imputed to the Haplotype Reference Consortium (HRC) release 276 1.1 (59), with further details in Li-Gao et al (38).

#### **Construction of the BMI polygenic score**

A polygenic score for BMI (BMI-PGS) was derived for each individual using variants 279 previously and independently associated with BMI (n=656) at a p-value less than  $1 \times 10^{-8}$  from the study by Yengo et al (60). To ensure the integrity of the PGS only those genetic variants, in the NEO genotype dosage data set, where the effect allele, the alternative allele, and the

- 282 minor allele frequency (+/-0.1) matched the data from Yengo et al were retained. If a match could not be made, then that SNP was dropped. All effect estimates were aligned to be positive, such that the effect allele was always that which increased an individual's genotype
- 285 predicted BMI. Finally, a weighted PGS was constructed by weighting the number of BMI increasing alleles, at each SNP (n=646, after data harmonization), by the effect estimate for that SNP and then summing across all values (60). The R script "01 generate bmi grs.R" for

288 deriving the PGS can be found in the github repository https://github.com/hughesevoanth/NEO\_BMI\_Metabolite\_MR.

### **Observational and Mendelian randomization analysis**

- 291 Two observational association analyses were undertaken in cross-section. The first was an association analysis between individual metabolite traits and BMI. The second uses a PGS as a proxy instrument for the exposure in a Mendelian randomization framework to provide an
- estimate of the causal effect of the exposure on outcome (here dietary state specific metabolite values). We will refer to the first as an observational analysis and the later as an MR analysis.
- 297 Observational analyses were performed by a multivariable generalized linear regression with sampling data, sub-population, age, and sex as additional covariables taking the form of glm(metabolite ~ visit date + sub-population + age + sex + BMI). For each generalized linear

300 model we also perform a Breusch-Pagan test of homoskedasticity using the bptest() function from the lmtest R package (61). In addition, for each association analysis we performed a Type I analysis of variance or ANOVA producing a table of deviances and estimated an eta-

- 303 squared statistic ( $\eta^2$ ), providing an estimate of the variance explained, for the model and for the primary exposure, BMI (**S3 File**).
- 306 One-sample Mendelian randomization analyses were performed using the ivreg R package (<u>https://cran.r-project.org/web/packages/ivreg/</u>), which implements a two-stage least squares instrumental variable analysis. In all instances and given the relative viability of BMI
- 309 instruments versus reciprocal metabolite instrumentation, BMI was defined as our exposure, the PGS described above is our instrument for BMI and each metabolite trait was iteratively defined as the outcome. The same model and covariables as described in the association
- 312 analysis paragraph above was used here. Along with MR effect estimates, we also report the Breusch-Pagan test of homoskedasticity, the F-statistic and F-test p-value testing for weak instruments, and summary statistics for the Durbin-Wu-Hausman endogeneity test (S3 File).
- 315

Unless stated otherwise - because our outcomes are rank normal transformed (zero centered with a standard deviation of one) - the effect estimates (beta) and standard errors (se) are

318 reported as rank normalized standard deviation units change per unit increase in BMI in kilograms per meter-squared (kg/m<sup>2</sup>).

#### 321 Study structure

In all observational and MR analyses, four (sub-)population analyses were performed. The primary analysis, in all instances, was a weighted NEO (wNEO) analysis using data from all

- 324 available samples. The wNEO analyses included weights for each sample that were previously derived to have the Leiden sub-population BMI distribution emulate that of the randomly sampled Leiderdorp sub-population (62). Sensitivity analyses include (1) a Leiderdorp sub-
- 327 population analysis, (2) an un-weighted NEO analysis, and (3) a Leiden sub-population analysis. In addition, sex specific analyses were carried out using the primary weighted NEO framework and the Leiderdorp sub-population, as neither have a sampling bias in there BMI
- 330 distributions.

#### **Code availability**

All statistical analysis were conducted in the R language (v 4.0.2, Taking Off Again), and all

333 bespoke functions and analytical code for the study can be found in the github repository https://github.com/hughesevoanth/NEO\_BMI\_Metabolite\_MR.

### **Results**

#### 336 **NEO cohort description**

Following quality control and derivation of the response trait the data set consisted of 5517 individuals (51.6% female), 687 metabolite traits (229 fasting, 229 postprandial, 229

- response) and 85 covariables. The average age of participants was 56 years, with an average BMI of 29.98 kg/m<sup>2</sup> (Table 1).
- The NEO cohort is made up of two distinct sub-samples, (1: "Leiderdorp") a randomly sampled population of 1,406 individuals from the municipality of Leiderdorp (mean BMI = 26.24 kg/m<sup>2</sup>, 95% quantile interval (QI)19.94-37.2), and (2: "Leiden") a sample population of
- 4,111 participant from the city of Leiden who were oversampled for individuals with a BMI greater than 27 kg/m<sup>2</sup> (mean BMI = 31.26 kg/m<sup>2</sup>, 95% QI 26.02-42.18). BMI distributions differed between the two sub-populations (generalized linear model (glm) Student's t test p-
- value = 3.66x10<sup>-280</sup>, S1 Fig.). In addition, the two sub-populations also differ in sex ratio, alcohol intake (g/day), smoking (packyears), educational attainment and BMI polygenic score (BMI-PGS; generalized linear model Student's t test p-value < 1.95x10<sup>-2</sup>), but not in age or
- 351 height (**Table 1**). Whilst the variance explained by sub-populations is large for BMI (20.7%) and closely related traits (weight, hip and waist circumference), it is an order smaller for other

variables like BMI-PGS, packyears, and educational attainment (variance explained by subpopulation < 2%, **Table 1**).

\_ . . . . . .

### **Description of metabolite data**

Of the 229 assayed metabolites 98 are lipoproteins and their particle concentrations and an

- additional 70 are lipoprotein ratios. The expected lipid concentrations were observed across
   lipoprotein classes (S4 Fig.). Namely, triglycerides dominate VLDLs, cholesterol dominates
   IDL and LDLs, and phospholipids and cholesterol dominate HDLs, on average. This remains
- true in both the fasting and postprandial data. All bar 14 metabolites differed in mean concentration or ratio between the fasted and postprandial states (paired t-test, P < 0.05/229, Table S3 in S1 File). These 14 include the concentration of particles: total lipids, total</li>
- 363 cholesterol, cholesterol esters, and free cholesterol in medium LDL. It also includes total cholesterol in LDL, large LDL, and small LDL, and cholesterol esters in small LDL. Overall, 126 metabolites increased in abundance, and 89 decreased postprandially (Table S3 in S1
- 366 File). Those with the largest scaled and centred, mean increase were the amino acids tyrosine, leucine, valine, isoleucine, and phenylalanine (S5 Fig.). Those with the largest mean decrease were the ratio of saturated fatty acids to total fatty acids, the ratio of triglycerides to total
- 369 lipids in very large VLDL, the ratio of phospholipids to total lipids in small VLDL and the ketone body 3-hydroxybutyrate (Table S3 in S1 File). For all metabolites, 150-minute postprandial change was not in the same direction for all participants (S5 Fig.).

372

354

#### The observational effect of BMI on metabolite trait variation

- wNEO observational analyses suggested broad association between BMI and metabolite 375 traits, with 473 metabolite traits (across fasting, postprandial, and response states) showing evidence of association with BMI ( $P < 1.163 \times 10^{-3}$ , Fig. 2, S6 Fig, and S3 File). Effect estimates correlated between sexes (Pearson's r = 0.965), but more associations were
- observed in women (426 total: 162 fasting, 175 postprandial, 89 response) than men (369 total: 161 fasting, 168 postprandial, 40 response, Fig. 3A). A total of 333 associations were shared between men and women, with 93 specific to women, 36 specific to men, and 225
- metabolite traits having no association with BMI in either sex (S3 File). Among the associated traits all but 10 are directionally consistent among men and women (Fig. 3A).
   Larger effect sizes were observed in men (mean absolute beta = 0.0356) than women (mean
- beta = 0.0291), across all traits on average (Fig. 3A), but the variance explained by BMI,

across all traits on average was similar among men and women ( $\eta^2$ : men = 1.737%, women = 1.734%).

387

#### Observational results - fasting

A total of 175 or 76% of fasting traits showed evidence of association with BMI. The

- 390 strongest association observed was with the inflammation marker glycoprotein acetyls (beta = 0.081, se = 0.0037, P =  $2.89 \times 10^{-101}$ ). This was followed closely by the branched chain amino acids isoleucine (beta = 0.072, se = 0.0033, P =  $4.18 \times 10^{-101}$ ), leucine (beta = 0.066, se =
- 393 0.0031, P =  $1.16x10^{-94}$ ) and valine (beta = 0.067, se = 0.0032, P =  $8.70x10^{-92}$ ). The strongest inverse associations were observed for average diameter of HDL particles (beta = -0.071, se = 0.0035, P =  $6.74x10^{-95}$ ), the ratio of free cholesterol to total lipids in IDL (beta = -0.078, se =
- 396 0.0036, P =  $1.04x10^{-100}$ ) and large HDL (beta = -0.077, se = 0.0037, P =  $8.09x10^{-95}$ ). If data is summarized by metabolite annotation class (**Table S1** in **S1 File**), we find that the classes with the largest average absolute BMI effect are inflammation (average absolute beta =
- 0.081), amino acids (0.051), lipoprotein particle size (0.049) and glycolysis related metabolites (0.049). Those with the smallest average absolute effect are ketone bodies (0.021), fluid balance (0.019) and fatty acids (0.018) (S6 Fig.).

402

#### Observational results - postprandial

A total of 188 or 82% of postprandial traits showed evidence of association with BMI. Fasting

- 405 and postprandial point estimates correlate strongly (Pearson's r = 0.976) with each other, with no mean difference in their distributions (t-test P = 0.83) and 166 shared associations. However, 31 associations are unique to one of the two dietary states, with nine associations
- specific to fasting and 22 specific to postprandial data (Fig. 3C). We tested for a difference in effect estimates between the dietary states and observed 14 estimates to differ (z-test, P<0.05/229, Fig. 3C). Eight of those 14 are amino acids (tyrosine, alanine, phenylalanine,</li>
- 411 histidine, valine, leucine, glutamine, and isoleucine). The other six that differ between dietary states include four very large HDL ratios, the ketone beta-hydroxybutyrate (bohbut) and the glycolysis related metabolite lactate (lac).

414

#### **Observational results - response**

A total of 70 response traits showed evidence of a positive association with BMI and 40 traits

417 had an inverse association. Response and fasting (Pearson's r = 0.34,  $P = 1.39 \times 10^{-7}$ ), and response and postprandial (Pearson's r = 0.514,  $P = 7.96 \times 10^{-17}$ ) point estimates modestly

correlate with each other, indicative of the relative independence of the response trait. The

- 420 strongest associations were all amino acids, which (ordered by association P-value: tyrosine, alanine, phenylalanine, leucine valine, glutamine, histidine, and leucine) were all inversely associated with BMI (**S6 Fig.**). For example, while alanine levels (fasting mean = 0.359
- 423 mmol/L) were elevated after a liquid mixed meal (postprandial mean = 0.376 mmol/L, paired t-test P =  $2.53 \times 10^{-181}$ ) the effect attenuated as BMI increased (beta = -0.056, se = 0.004, P =  $5.72 \times 10^{-51}$ , **Fig. 4a**) such that the effect of BMI on alanine response was negative (**Fig. 4b**).
- 426 This relationship was observed for all amino acids in the data set (**Fig. 2**).

The strongest positive response association was observed for triglycerides in very large HDL

- 429 (xlhdltg: beta = 0.037, se = 0.004, P = 5.88x10<sup>-21</sup>). This was followed closely by the ratio of (1) cholesterol esters, (2) triglycerides, and (3) total cholesterol to total lipids in very large HDL. Conversely, the response trait ratio of phospholipids to total lipids in very large HDL
- decreased as BMI increased. This suggests that following a liquid mixed meal the increase of phospholipids relative to total lipids in very large HDL is attenuated by BMI and conversely, the ratio of cholesterol and triglycerides to total lipids in very large HDL increased as BMI
- 435 increased (Fig. 2).

Outside of amino acids and lipoproteins, other metabolite response traits that had a positive association with BMI included 3-hydroxybutyrate (ketone body), creatinine (fluid balance), linoleic acid, and total fatty acids (fatty acids). Others with an inverse association with BMI included glucose and lactate (glycolysis), the ratio of linoleic acid to total fatty acids, and the

441 ratio of omega-6 fatty acids to total fatty acids (fatty acid ratios; S3 File).

#### **Possible confounders**

- The instrumental variable used, BMI-PGS, explains 4.7% of the variation in BMI, and for each unit increase in BMI-PGS there is a 3.26 (se = 0.20) unit (kg/m<sup>2</sup>) increase in BMI (P =  $3.61 \times 10^{-60}$ , wNEO analysis, **Table 1**). An assessment of the correlation between BMI and
- 447 BMI-PGS with study covariables was performed to identify possible confounders, specifically those that would violate the second MR assumption (exchangeability). Of the 91 tested covariables, 60 were associated with BMI (wNEO,  $P < 9.26 \times 10^{-4}$ ; Table S4 in S1 File and S7
- 450 Fig.), and 17 were associated with BMI-PGS (S8 Fig.). Those 17 that associated with BMI-PGS included other adiposity traits (n = 5), sub-population, visit date, genetic principal

component 3, (imputed) smoking packyears, on a weight loss diet, type of diet, on a diet last

- 453 month, a food rule, mean CO<sub>2</sub> production, and a peroxidation sample quality flag. The 17 covariables associated the BMI-PGS were tested for an association with each metabolite trait (the outcomes) in a univariable linear model. Results illustrated broad association across all
- 456 traits and covariables, defining each covariable as a confounder in MR analysis leading to sensitivity analyses discussed below (S9 Fig.). A more comprehensive description of these analyses is in S1 Text.

459

#### Estimating the causal effect of BMI on metabolite trait variation

- MR analyses (wNEO) support broad associations between BMI and metabolites as suggested
  by the overall strong correlation between observational and MR estimates (Pearson's r = 0.852, P = 1.02x10<sup>-194</sup>, intercept = 1.54x10<sup>-03</sup>, slope = 0.911). The correlation was strongest for postprandial traits (Pearson's r = 0.921, P = 4.44x10<sup>-95</sup>, intercept = 3.59x10<sup>-03</sup>, slope = 0.922) and weaker for fasting (Pearson's r = 0.871, P = 7.71x10<sup>-72</sup>, intercept = 7.62x10<sup>-03</sup>,
- slope = 0.855) and response traits (Pearson's r = 0.62,  $P = 1.11 \times 10^{-25}$ , intercept = -6.36<sup>-03</sup>, slope = 1.08, **Figure 3D**). Forty-two observational and MR effect estimates showed evidence of being different from each other (z-test P< 0.05), yet none remain so after correcting for
- multiple tests (P < 0.05/687). Overall, these observations indicate that cross-sectional estimates have reasonable power at predicting MR estimates for these exposure-outcome
- 471 analyses, consistent with previous work (18).
- A total of 201 metabolite traits (across fasting, postprandial, and response states; Figure 5, S3
  File) showed nominal evidence of association (P < 0.05) with BMI and 20 (Table 2, Figure 6) showed evidence of association with BMI (P < 1.16x10<sup>-3</sup>; S10 Fig.). MR effect estimates varied more between sexes (Pearson's r = 0.368, p = 1.93x10<sup>-23</sup>) than observed in
- 477 observational results, with 86 showing evidence of being different from each other (z-test P< 0.05), yet none remaining so after correcting for multiple tests (P < 0.05/687). Nine metabolite traits (7 fasting, 2 response) showed evidence of association with BMI in females, eight of
- 480 which were unique to females (**Figure 6**). This included fasting small HDL triglycerides (shdltg\_f) and fasting very small VLDL triglycerides (xsvldltg\_f), both of which increased with increases in BMI. In contrast, five metabolites were associated with BMI in men, one of
- 483 which was unique to men postprandial glutamine, which had an inverse relationship with BMI (gln\_p; **Figure 6**). The other four metabolites shared an association with the general

population. They are, fasting and postprandial citrate (cit f, cit p), and the ratio of linoleic

- 486 acid to total fatty acids in both the fasting and postprandial state (lafa\_f, lafa\_p). Each of which were also inversely associated with BMI. On average MR effect estimates were larger in females (absolute mean beta = 0.047) than males (absolute mean beta = 0.026, paired t-test
- 489  $P = 1.43 \times 10^{-45}$ ).

#### MR results - fasting

- A total of 87 fasting traits exhibited nominal evidence of an association with BMI in the general population, five remained after correction for multiple testing (Table 2, Figure 6, S3 File). The strongest association observed was with the ratio of linoleic acid to total fatty acids
- 495 (lafa; beta = -0.106, se = 0.025, P =  $1.80 \times 10^{-5}$ ). This was followed closely by 4 other inverse associations: the ratio polyunsaturated fatty acids (pufafa; beta = -0.081, se = 0.024, P =  $6.80 \times 10^{-4}$ ) to total fatty acids, the ratio omega-6 to total fatty acids (faw6fa; beta = -0.081, se
- 498 = 0.024, P =  $6.97x10^{-4}$ ) and the abundance of citrate (cit; beta = -0.079, se = 0.024, P =  $8.63x10^{-4}$ ). In addition, one fasting metabolite showed evidence of a positive association with BMI, the branched-chain amino acid leucine (leu; beta = 0.068, se = 0.020, P =  $5.62x10^{-4}$ ). If
- 501 data is summarized by metabolite annotation class (Table S1 in S1 File), we find that the classes with the largest average absolute BMI effect are ketone bodies (average beta = -0.047, n = 2), amino acids (0.036, n = 8), inflammation (0.029, n = 1), glycerides and phospholipids
- 504 (0.027, n = 9) and lipoprotein subclasses (0.023, n = 98). Those with the smallest average absolute effect are lipoprotein particle size (0.009, n = 3), lipoprotein subclass ratios (0.003, n = 70), and cholesterol (0.002, n = 9) (S10 Fig.).

507

#### MR results - postprandial

A total of 96 postprandial metabolites exhibited nominal evidence of an association with BMI,
12 remained after correcting for multiple testing (Table 2, Figure 6, S3 File). Like the fasting metabolite traits the fatty acid ratios linoleic acid (lafa; beta = -0.092, se = 0.025, P = 2.0x10<sup>-</sup>

<sup>4</sup>), omega-6 (faw6fa; beta = -0.080, se = 0.024, P =  $7.83 \times 10^{-4}$ ), polyunsaturated fatty acids

- 513 (pufafa; beta = -0.077, se = 0.024, P =  $1.10 \times 10^{-3}$ ) and citrate (cit; beta = -0.105, se = 0.022, P =  $2.83 \times 10^{-6}$ ), who had the largest effect, each also had an inverse relationship with BMI (**Figure 5-6**). In addition, the amino acid histidine (his), large HDL cholesterol (l.hdl.c) and
- 516 free cholesterol (l.hdl.fc) decreased with increases in BMI. Further, the ratio of cholesterol (l.hdl.c.pct), cholesterol esters (l.hdl.ce.pct), and free cholesterol (l.hdl.fc.pct) to total lipids in HDL decreased with increases in BMI. Finally, the ratio of free cholesterol to total lipids in

- 519 IDL (idl.fc.pct) and the ratio of phospholipids to total lipids in medium VLDL (m.vldl.pl.pct) decreased with increases in BMI. If data is summarized by metabolite annotation class (Table S1 in S1 File), we find that the classes with the largest average absolute BMI effect are
- 522 glycolysis related metabolites (average beta = -0.046, n = 3), inflammation (0.40, n = 1) and lipoprotein subclasses (0.02, n = 98). The average effect among amino acids is not negative (-0.019, n = 8) in opposition to that seen in fasting data (**S10 Fig.**).
- 525

#### MR results - response

- A total of 18 response metabolites exhibited nominal evidence of an association with BMI,
  three remained after correcting for multiple testing (Table 2, Figure 6, S3 File). The largest effect was observed for the amino acid alanine (ala: beta = -0.081, se = 0.023, P = 5.91x10<sup>-04</sup>). Data suggested that increases in BMI attenuates the increase in abundance of the amino acid
- alanine after a liquid mixed meal (Figure 5-6) consistent with observational analyses above (Figure 4). The other two response traits that associated with BMI are the ratio of phospholipids in medium VLDL to total lipids in medium VLDL (m.vldl.pl.pct; beta = 0.091,
- 534 se = 0.027, P = 6.75x10<sup>-4</sup>) and the ratio of free cholesterol in small VLDL to total lipids in small VLDL (s.vldl.fc.pct; beta = 0.082, se = 0.025, P =  $1.11x10^{-3}$ ). As a class, amino acids (average beta = -0.059, n=8) had the largest average BMI response effect estimate (S10 Fig.).
- 537 This was followed by the ketone bodies acetate and beta-hydroxybutyrate (mean beta = 0.048, n = 2) and the glycolysis related metabolites citrate, glucose, and lactate (mean beta = -0.042, n = 3).
- 540

#### Sub-population and sensitivity analyses

- 543 All observational and MR analyses were repeated in each of the two sub-populations and in the NEO cohort without the inclusion of weights. These analyses allowed us to evaluate the variability in effect estimates measured in a random (Leiderdorp) and biased (Leiden)
- 546 population sample as well as the effectiveness of the weights in our primary analyses (wNEO). We found that effect estimates from the Leiderdorp and the wNEO frameworks are strongly correlated (observational Pearson's r = 0.983, MR = 0.855) and correlation
- 549 coefficients weakened when compared to the un-weighted NEO and the Leiden frameworks (S11 Figure). Decreases in agreement between analyses as the sample population mean BMI shifts would indicate that there are either un-accounted confounders influencing the results or
- that the relationship between BMI and metabolite trait variation is not always linear.

To evaluate the influence of confounders on MR effect estimates we reran the association analysis in the wNEO data set. Three additional covariates were included in the model (smoking, on a weight loss diet, and PC3) and 101 sample with a peroxidation sample quality flag, a sample quality metric identified by Metabolon, were removed. Overall primary

558 (wNEO) observational (Pearson's r = 0.998) and MR (Pearson's r = 0.963) effect estimates correlate strongly with those from the sensitivity analysis (S7 File). A more comprehensive description of these analyses is in S1 Text.

### 561 **Discussion**

555

This study provides effect estimates for observational and MR associations between BMI and 564 metabolites in a (1) fasted, (2) postprandial, and (3) response state, using individual level data from a middle-aged cohort of 5517 individuals of Northern European ancestry including a liquid mixed meal challenge. Each dietary state provides a unique examination at metabolite

- 567 variation, the value of which are actively being explored. Broad observational associations were observed between BMI and metabolites (69% of tested traits). In addition, MR estimates were largely concordant with the observational estimates (Figure 3D). This is consistent with
- 570 previous research and suggests that, at least for this lipidomic platform, observational estimates are reasonably well aligned to MR effect estimates (18). This generalization holds less true for response traits than for postprandial and fasting trait (**Figure 3D**). After
- 573 correcting for multiple testing, 20 metabolite traits maintain evidence of a causal BMI effect (Figure 6). This includes the inverse association with fasting and postprandial ratios of linoleic acid (lafa), omega-6 (faw6fa), and polyunsaturated fatty acids (pufafa) to total fatty
- 576 acids and fasting and postprandial citrate (cit) abundance. In addition, the amino acid leucine has a positive MR association with BMI in the fasting state, histidine has an inverse MR association with BMI in the postprandial state and alanine has an inverse MR association with
- 579 BMI in the response state.

We compared our observational effect estimates to fifty-seven matching fasting metabolites 582 measured using the same platform, in a young adult cohort (18). Overall effect estimates correlated well (Pearson's r = 0.82), with the caveat that estimates cannot be directly compared given differences in data transformations between the studies. However, there are

- 585 37 shared associations, 6 unique to this study, 12 unique to the other and 2 yielding no association in either study (**Figure 3B**). Five of the shared associations were different across studies (total cholesterol, sphingomyelins, phosphatidylcholines, phosphoglycerides, and
- 588 linoleic acid). Among the 12 metabolites unique to existing work before that presented here, are 10 metabolites that previously exhibited a strong positive effect but showed no evidence for an association or negative point estimates here (total lipids in IDL, large LDL, medium
- 591 LDL and small LDL, total cholesterol in IDL and LDL, and four fatty acid metabolites omega-3, omega-6, polyunsaturated fatty acids, and docosahexaenoic acid). These differences may be the product of non-linear associations between these metabolites and BMI in
- 594 combination with age effects and differences in the distribution of BMI between these studies. Despite these difference, 57 fasting MR estimates that did overlap with previous work showed strong correlation between the two studies (Person's r = 0.862,  $P = 7.99 \times 10^{-18}$ ; **S12 Fig.**), with
- 597 one shared fasting MR association the amino acid leucine.

Given the prevalence of lipoproteins and their lipids on this platform we looked for the

- expected atherogenic lipoprotein profile that is decreases in HDL and increases in non-HDL lipoproteins with increase in BMI (63–66). Both observational and MR associations between BMI and fasting and postprandial dietary states do suggest a worsening atherogenic
- 603 lipoprotein profile with BMI (**Figure 7, S13 Fig,** and **S14 Fig.**). As illustrated with the fasting observational effect estimates in **Figure 7**, the atherogenic VLDL lipoproteins are higher with increases in BMI while non-atherogenic lipoproteins or those involved in the reverse
- 606 cholesterol transport system (HDL), were lower. In contrast to expectations, other atherogenic lipoproteins IDL and LDL, largely do not associate with BMI. In addition, triglycerides in non-atherogenic medium HDL and small HDL increase with increases in BMI. Further, as
- 609 HDL lipoprotein density increases the inverse relationship with BMI weakens and as seen with small HDL the association becomes positive (**Figure 7**). This is consistent with the observation above that the strongest inverse association with BMI is that with average
- 612 diameter of HDL particles, suggesting that as BMI increases there is a associated shift toward smaller HDL particle size. Along with these changes, other observations were consistent with obesity influencing lipid profiles that are associated with cardiometabolic disease (17,25,67).
- 615 These included increases in apolipoprotein B, decreases in apolipoprotein A-1 and increases in the ratio of B to A-1 with increases in BMI, in both the fasting and postprandial states (65,68).

The MR association of BMI across branched chain (BCAA) and aromatic (AAA) amino acids were similar with positive effects in the fasting state, no effect in the postprandial state, and an

- 621 inverse association in the response state (**Figure 2 and 5**). Meanwhile the dietary profile of (glucogenic) amino acids suggest no effect in the fasting state and inverse effects in both the postprandial and response states. These observations may suggest that BMI may have a causal
- 624 influence on the synthesis or metabolism of amino acids in general, particularly regarding their inverse association with BMI in the response state (**Figure 2 and 5**). BCAAs and AAAs have long been associated with obesity, glucose, insulin (resistance), and type 2 diabetes (69–
- 627 75). In support of early observations, numerous recent studies that have shown associations between amino acids and BMI, visceral adipose tissue and weight change (18,36,76–78), between BCAAs and AAAs with insulin resistance and type 2 diabetes (79–82), used MR to
- 630 show that insulin resistance increase BCAAs concentration (83) and used a randomized control trail to show that restricting BCAAs can improve glucose tolerance and reduce fat accumulation (84). Indeed evidence now suggests a potential causal pathway from BMI to
- 633 type 2 diabetes via the intermediate traits of insulin resistance and BCAAs, respectively (83). Observations here reinforce the causal association between BMI and amino acids, with the additional observations that postprandial abundance of the glucogenic amino acids decreases
- 636 with BMI and that the relative change in amino acid abundance in response to a liquid mixed meal decreases with increases in BMI.
- 639 As the study was centered in the Netherlands, study samples were limited to individuals of Northern European ancestry and as such inferences made from results should be limited to populations of similar ancestry and environment. Sampling was limited to individuals of
- 642 middle age (range 44 to 66 years and a mean of 56, Table 1). Whilst this provides specificity to a middle age population it also limits the results to this population age range as well. The NEO population sampling was performed in two distinct batches, one focused on
- 645 oversampling individuals of high BMI (Leiden) and a second a random and representative sampling of the population (Leiderdorp). The product of this led to the use of weighted linear regression analyses to maintain sample size and power, while also providing estimates that are
- 648 representative of the study population at large. The validity of this assumption rests in the credibility of the weights, which were specifically designed to make the BMI distribution of the Leiden sample mirror that of the Leiderdorp sample (85). We have illustrated through
- 651 comparison with the Leiderdorp sample that effect estimates are consistent across the two analyses, imparting support to the weighted analysis (**S11 Figure**). With these factors, there

was just a single postprandial time point evaluated here limiting the inferences that can be

- drawn. It is reasonable to speculate that an earlier time point, or a complete time series would provide additional information about how BMI might influence postprandial variation.Finally, while a single complex meal standardizes the complexities in evaluating metabolite
- 657 response and postprandial abundances alternative meals could provide novel insights in the interplay between BMI, nutrition, and metabolite variation.
- 660 In conclusion, using a middle-aged cohort of 5517 individuals we have demonstrated that effect estimates for BMI on metabolite traits in the fasting, postprandial and response dietary states. We have been able to show that results are broadly correlated between observational
- 663 and one-sample Mendelian randomization analyses and in the context of the numerous documented associations between BMI, metabolites and disease, this gives support to a conclusion that metabolites may act as intermediates – or at the least biomarkers of underlying
- 666 driver physiology between adiposity accumulation and disease. Furthermore, this work suggests that the dynamic metabolome may potentially flag common biological events which will systematically vary by BMI, which may be linked to the aetiology of disease and which

are linked to life course events such as feeding and metabolic response.

### Acknowledgements

- The authors thank all individuals who participated in the Netherlands Epidemiology of
  Obesity study, and all participating general practitioners for inviting eligible participants. We also thank the NEO study group, Pat van Beelen and all research nurses for data collection,
  Petra Noordijk and her team for laboratory management, and Ingeborg de Jonge for data
- 675 management of the NEO study. We acknowledge the support from the Netherlands Cardiovascular Research Initiative: an initiative with support of the Dutch Heart Foundation (CVON2014-02 ENERGISE). We thank Nutricia Research, Utrecht, The Netherlands, for
- providing the liqud mixed meal. Nicholas J. Timpson is a Wellcome Trust Investigator
   (202802/Z/16/Z), is the PI of the Avon Longitudinal Study of Parents and Children (MRC & WT 102215/2/13/2), is supported by the University of Bristol NIHR Biomedical Research
- 681 Centre (BRC-1215-20011), the MRC Integrative Epidemiology Unit (MC\_UU\_12013/3) and works within the CRUK Integrative Cancer Epidemiology Programme (C18281/A19169).
   David A. Hughes is supported by N.J.Timpson's Wellcome Investigator Award
- 684 (202802/Z/16/Z), and along with Caroline Bull is also supported by the University of Bristol

and UK Medical Research Council (MC\_UU\_00011/1 and MC\_UU\_00011/6). Dennis Mook-Kanamori is supported by Dutch Science Organization (ZonMW-VENI Grant 916.14.023)

### **References**

695

705

- 1. Bentham J, Di Cesare M, Bilano V, Bixby H, Zhou B, Stevens GA, et al. Worldwide trends in 690 body-mass index, underweight, overweight, and obesity from 1975 to 2016: a pooled analysis of 2416 population-based measurement studies in 128.9 million children, adolescents, and adults. Lancet. 2017;390(10113):2627-42.
  - 2. Yanovski JA. Obesity: Trends in underweight and obesity - scale of the problem. Nat Rev Endocrinol [Internet]. 2018;14(1):5-6. Available from: http://dx.doi.org/10.1038/nrendo.2017.157
  - 3. World Health Organization. World Health Organization. Obesity and Overweight Fact Sheet. [Internet]. 2021 [cited 2022 Mar 1]. Available from: https://www.who.int/en/newsroom/fact-sheets/detail/obesity-and-overweight
- 4. Clinical Guidelines on the Identification, Evaluation, and Treatment of Overweight and 700 Obesity in Adults--The Evidence Report. National Institutes of Health. Obes Res. 1998 Sep;6 Suppl 2:51S-209S.
  - 5. Jensen MD, Ryan DH, Apovian CM, Ard JD, Comuzzie AG, Donato KA, et al. 2013 AHA/ACC/TOS guideline for the management of overweight and obesity in adults: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines and The Obesity Society. J Am Coll Cardiol. 2014 Jul;63(25 Pt B):2985-3023.
  - 6. Okorodudu DO, Jumean MF, Montori VM, Romero-Corral A, Somers VK, Erwin PJ, et al. Diagnostic performance of body mass index to identify obesity as defined by body adiposity: a systematic review and meta-analysis. Int J Obes (Lond). 2010 May;34(5):791-9.
- 7. Reilly JJ, Kelly J, Wilson DC. Accuracy of simple clinical and epidemiological definitions of 710 childhood obesity: systematic review and evidence appraisal. Obes Rev an Off J Int Assoc Study Obes. 2010 Sep;11(9):645-55.
  - 8. Javed A, Jumean M, Murad MH, Okorodudu D, Kumar S, Somers VK, et al. Diagnostic performance of body mass index to identify obesity as defined by body adiposity in children and adolescents: A systematic review and meta-analysis. Pediatr Obes. 2015;10(3):234-44.
- 715 9. Reilly JJ, El-Hamdouchi A, Diouf A, Monyeki A, Somda SA. Determining the worldwide prevalence of obesity. Lancet [Internet]. 2018;391(10132):1773–4. Available from: http://dx.doi.org/10.1016/S0140-6736(18)30794-3
  - 10. Wade KH, Carslake D, Tynelius P, Smith GD, Martin RM. Variation of all-cause and causespecific mortality with body mass index in one million Swedish parent-son pairs: An instrumental variable analysis. PLoS Med. 2019;16(8):1-15.
    - 11. Jenkins DA, Wade KH, Carslake D, Bowden J, Sattar N, Loos RJF, et al. Estimating the causal effect of BMI on mortality risk in people with heart disease, diabetes and cancer using Mendelian randomization. Int J Cardiol [Internet]. 2021;330:214–20. Available from: https://doi.org/10.1016/j.ijcard.2021.02.027
- 725 12. Solomon CG, Manson JE. Obesity and mortality: a review of the epidemiologic data. Am J Clin Nutr. 1997 Oct;66(4 Suppl):1044S-1050S.

- 13. Reis JP, Macera CA, Araneta MR, Lindsay SP, Marshall SJ, Wingard DL. Comparison of overall obesity and body fat distribution in predicting risk of mortality. Obesity (Silver Spring). 2009 Jun;17(6):1232–9.
- Pearson-Stuttard J, Zhou B, Kontis V, Bentham J, Gunter MJ, Ezzati M. Worldwide burden of cancer attributable to diabetes and high body-mass index: a comparative risk assessment. lancet Diabetes Endocrinol. 2018 Jun;6(6):e6–15.
  - 15. Lauby-Secretan B, Scoccianti C, Loomis D, Grosse Y, Bianchini F, Straif K. Body Fatness and Cancer--Viewpoint of the IARC Working Group. N Engl J Med. 2016 Aug;375(8):794–8.
- 73516.Sung H, Siegel RL, Torre LA, Pearson-Stuttard J, Islami F, Fedewa SA, et al. Global patterns in<br/>excess body weight and the associated cancer burden. CA Cancer J Clin. 2018;88–112.
  - 17. Powell-Wiley TM, Poirier P, Burke LE, Després J-PP, Gordon-Larsen P, Lavie CJ, et al. Obesity and Cardiovascular Disease: A Scientific Statement from the American Heart Association. Circulation. 2021 May;143(21):E984–1010.
- 18. Würtz P, Wang Q, Kangas AJ, Richmond RC, Skarp J, Tiainen M, et al. Metabolic Signatures of Adiposity in Young Adults: Mendelian Randomization Analysis and Effects of Weight Change. Sheehan NA, editor. PLoS Med [Internet]. 2014 Dec 9;11(12):e1001765. Available from: https://dx.plos.org/10.1371/journal.pmed.1001765
- Würtz P, Havulinna AS, Soininen P, Tynkkynen T, Prieto-Merino D, Tillin T, et al. Metabolite
   Profiling and Cardiovascular Event Risk: A Prospective Study of 3 Population-Based Cohorts. Physiol Behav. 2016 Mar;176(1):139–48.
  - 20. von Krüchten R, Lorbeer R, Müller-Peltzer K, Rospleszcz S, Storz C, Askani E, et al. Association between Adipose Tissue Depots and Dyslipidemia: The KORA-MRI Population-Based Study. Nutrients. 2022;14(4).
- 750 21. Ference BA, Yoo W, Alesh I, Mahajan N, Mirowska KK, Mewada A, et al. Effect of long-term exposure to lower low-density lipoprotein cholesterol beginning early in life on the risk of coronary heart disease: A Mendelian randomization analysis. Ration Pharmacother Cardiol [Internet]. 2012/10/23. 2013;9(1):90–8. Available from: http://www.ncbi.nlm.nih.gov/pubmed/23083789
- 755 22. Krittanawong C, Khawaja M, Rosenson RS, Amos CI, Nambi V, Lavie CJ, et al. Association of PCSK9 Variants With the Risk of Atherosclerotic Cardiovascular Disease and Variable Responses to PCSK9 Inhibitor Therapy. Curr Probl Cardiol. 2021 Nov;101043.
  - 23. Wilt TJ, Bloomfield HE, MacDonald R, Nelson D, Rutks I, Ho M, et al. Effectiveness of statin therapy in adults with coronary heart disease. Arch Intern Med. 2004 Jul;164(13):1427–36.
- Berliner JA, Navab M, Fogelman AM, Frank JS, Demer LL, Edwards PA, et al. Atherosclerosis:
   basic mechanisms. Oxidation, inflammation, and genetics. Circulation. 1995 May;91(9):2488– 96.
- Richardson TG, Sanderson E, Palmerid TM, Korpelaid MA, Ference BA, Smith GD, et al. Evaluating the relationship between circulating lipoprotein lipids and apolipoproteins with risk of coronary heart disease: A multivariable Mendelian randomisation analysis. PLoS Med [Internet]. 2020;17(3):1–22. Available from: http://dx.doi.org/10.1371/journal.pmed.1003062
  - 26. Ala-Korpela M. The culprit is the carrier, not the loads: Cholesterol, triglycerides and apolipoprotein B in atherosclerosis and coronary heart disease. Int J Epidemiol.

790

800

2019;48(5):1389-92.

- 770 27. Corbin LJ, Tan VY, Hughes DA, Wade KH, Paul DS, Tansey KE, et al. Formalising recall by genotype as an efficient approach to detailed phenotyping and causal inference. Nat Commun. 2018;9(1).
- 28. Fang S, Wade KH, Hughes DA, Fitzgibbon S, Yip V, Timpson NJ, et al. A multivariant recall-bygenotype study of the metabolomic signature of BMI. Obesity [Internet]. 2022 Jun 22 [cited 775 2023 Feb 27];30(6):1298–310. Available from: https://pubmed.ncbi.nlm.nih.gov/35598895/
  - Moreton JR. Chylomicronemia, fat tolerance, and atherosclerosis. Int J Epidemiol. 29. 2016;45(5):1372-9.
- 30. Karimpour M, Surowiec I, Wu J, Gouveia-Figueira S, Pinto R, Trygg J, et al. Postprandial metabolomics: A pilot mass spectrometry and NMR study of the human plasma metabolome 780 in response to a challenge meal. Anal Chim Acta [Internet]. 2016;908:121–31. Available from: http://dx.doi.org/10.1016/j.aca.2015.12.009
  - 31. Berry SE, Valdes AM, Drew DA, Asnicar F, Mazidi M, Wolf J, et al. Human postprandial responses to food and potential for precision nutrition. Nat Med [Internet]. 2020;26(6):964– 73. Available from: https://doi.org/10.1038/s41591-020-0934-0
- 785 32. Wang Q, Jokelainen J, Auvinen J, Puukka K, Keinänen-Kiukaanniemi S, Järvelin MR, et al. Insulin resistance and systemic metabolic changes in oral glucose tolerance test in 5340 individuals: An interventional study. BMC Med. 2019;17(1):1-12.

33. Bütikofer U, Burnand D, Portmann R, Blaser C, Schwander F, Kopf-Bolanz KA, et al. Serum metabolites responding in a dose-dependent manner to the intake of a high-fat meal in normal weight healthy men are associated with obesity. Metabolites. 2021;11(6).

- 34. Shrestha A, Müllner E, Poutanen K, Mykkänen H, Moazzami AA. Metabolic changes in serum metabolome in response to a meal. Eur J Nutr. 2017;56(2):671-81.
- 35. Labarre JL, Hirschfeld E, Soni T, Kachman M, Wigginton J, Duren W, et al. Comparing the fasting and random-fed metabolome response to an oral glucose tolerance test in children 795 and adolescents: Implications of sex, obesity, and insulin resistance. Nutrients. 2021;13(10):1– 17.
  - 36. Schutte BAM, Van Den Akker EB, Deelen J, Van De Rest O, Van Heemst D, Feskens EJM, et al. The effect of standardized food intake on the association between BMI and 1 H-NMR metabolites. Sci Rep [Internet]. 2016;6(December):1–6. Available from: http://dx.doi.org/10.1038/srep38980
  - 37. Stumvoll M, Mitrakou A, Pimenta W, Jenssen T, Yki-Järvinen H, Van Haeften T, et al. Use of the oral glucose tolerance test to assess insulin release and insulin sensitivity. Diabetes Care [Internet]. 2000 [cited 2023 Jan 16];23(3):295–301. Available from: https://pubmed.ncbi.nlm.nih.gov/10868854/
- 805 38. Li-Gao R, Hughes DA, van Klinken JB, de Mutsert R, Rosendaal FR, Mook-Kanamori DO, et al. Genetic Studies of Metabolomics Change After a Liquid Meal Illuminate Novel Pathways for Glucose and Lipid Metabolism. Diabetes [Internet]. 2021 Dec 1;70(12):2932-46. Available from: https://diabetesjournals.org/diabetes/article/70/12/2932/139064/Genetic-Studies-of-Metabolomics-Change-After-a
- 810 39. Wade KH, Lawlor D, Borges MC, Palmer T, Hartwig FP, Hemani G, et al. MR Dictionary

[Internet]. 2021 [cited 2022 Mar 1]. Available from: https://mr-dictionary.mrcieu.ac.uk

- 40. Davey Smith G, Hemani G. Mendelian randomization: genetic anchors for causal inference in epidemiological studies. Hum Mol Genet. 2014;23(R1):R89-98.
- 41. Bull CJ, Bell JA, Murphy N, Sanderson E, Davey Smith G, Timpson NJ, et al. Adiposity, 815 metabolites, and colorectal cancer risk: Mendelian randomization study. BMC Med [Internet]. 2020 Dec 1 [cited 2023 Jul 10];18(1). Available from: https://pubmed.ncbi.nlm.nih.gov/33327948/
  - 42. Kalaoja M, Corbin LJ, Tan VY, Ahola-Olli A V., Havulinna AS, Santalahti K, et al. The Role of Inflammatory Cytokines as Intermediates in the Pathway from Increased Adiposity to Disease. Obesity (Silver Spring) [Internet]. 2021 Feb 1 [cited 2023 Jul 10];29(2):428–37. Available from: https://pubmed.ncbi.nlm.nih.gov/33491305/

820

825

- 43. Fang S, Wade KH, Hughes DA, Fitzgibbon S, Yip V, Timpson NJ, et al. A multivariant recall-bygenotype study of the metabolomic signature of BMI. Obesity (Silver Spring) [Internet]. 2022 Jun 1 [cited 2023 Jul 10];30(6):1298–310. Available from: https://pubmed.ncbi.nlm.nih.gov/35598895/
- 44. Bell JA, Richardson TG, Wang Q, Sanderson E, Palmer T, Walker V, et al. Effects of general and central adiposity on circulating lipoprotein, lipid, and metabolite levels in UK Biobank: A multivariable Mendelian randomization study. Lancet Reg Heal Eur [Internet]. 2022 Oct 1 [cited 2023 Jul 10];21. Available from: https://pubmed.ncbi.nlm.nih.gov/35832062/
- 830 45. Bell JA, Carslake D, O'Keeffe LM, Frysz M, Howe LD, Hamer M, et al. Associations of Body Mass and Fat Indexes With Cardiometabolic Traits. J Am Coll Cardiol. 2018 Dec 18;72(24):3142–54.
  - 46. Wade KH, Carslake D, Sattar N, Davey Smith G, Timpson NJ. BMI and Mortality in UK Biobank: Revised Estimates Using Mendelian Randomization. Obesity. 2018 Nov 1;26(11):1796–806.
- 47. Goudswaard LJ, Bell JA, Hughes DA, Corbin LJ, Walter K, Davey Smith G, et al. Effects of 835 adiposity on the human plasma proteome: observational and Mendelian randomisation estimates. Int J Obes [Internet]. 2021 Oct 1 [cited 2023 Jul 10];45(10):2221–9. Available from: https://pubmed.ncbi.nlm.nih.gov/34226637/
- 48. Wade KH, Chiesa ST, Hughes AD, Chaturvedi N, Charakida M, Rapala A, et al. Assessing the Causal Role of Body Mass Index on Cardiovascular Health in Young Adults: Mendelian 840 Randomization and Recall-by-Genotype Analyses. Circulation [Internet]. 2018 Nov 13 [cited 2023 Jul 10];138(20):2187–201. Available from: https://pubmed.ncbi.nlm.nih.gov/30524135/
  - 49. Timpson NJ, Nordestgaard BG, Harbord RM, Zacho J, Frayling TM, Tybjærg-Hansen A, et al. Creactive protein levels and body mass index: Elucidating direction of causation through reciprocal Mendelian randomization. Int J Obes [Internet]. 2011 Feb [cited 2023 Jul 10];35(2):300–8. Available from: https://pubmed.ncbi.nlm.nih.gov/20714329/
- 50. Tan VY, Timpson NJ. The UK Biobank: A Shining Example of Genome-Wide Association Study Science with the Power to Detect the Murky Complications of Real-World Epidemiology [Internet]. Vol. 23, Annual Review of Genomics and Human Genetics. Annu Rev Genomics Hum Genet; 2022 [cited 2023 Feb 20]. p. 569-89. Available from: 850 https://pubmed.ncbi.nlm.nih.gov/35508184/
  - 51. de Mutsert R, den Heijer M, Rabelink TJ, Smit JW, Romijn JA, Jukema JW, et al. The Netherlands Epidemiology of Obesity (NEO) study: study design and data collection. Eur J Epidemiol [Internet]. 2013;28(6):513–23. Available from:

https://www.ncbi.nlm.nih.gov/pubmed/23576214

- 855 52. de Mutsert R, den Heijer M, Rabelink TJ, Smit JWA, Romijn JA, Jukema JW, et al. The Netherlands Epidemiology of Obesity (NEO) study: study design and data collection. Eur J Epidemiol [Internet]. 2013 Jun;28(6):513–23. Available from: https://www.ncbi.nlm.nih.gov/pubmed/23576214
- 53. Soininen P, Kangas AJ, Würtz P, Suna T, Ala-Korpela M. Quantitative serum nuclear magnetic
   resonance metabolomics in cardiovascular epidemiology and genetics. Circ Cardiovasc Genet.
   2015 Feb;8(1):192–206.
  - 54. Hughes DA, Taylor K, McBride N, Lee MA, Mason D, Lawlor DA, et al. Metaboprep: an R package for pre-analysis data description and processing. Bioinformatics. 2022 Feb;38(7):1980–7.
- 865 55. Cheverud JM. A simple correction for multiple comparisons in interval mapping genome scans. Heredity (Edinb). 2001;87(1):52–8.
  - 56. Li J, Ji L. Adjusting multiple testing in multilocus analyses using the eigenvalues of a correlation matrix. Heredity (Edinb) [Internet]. 2005 Sep 3 [cited 2019 Jun 24];95(3):221–7. Available from: http://www.nature.com/articles/6800717
- 57. Gao X, Starmer J, Martin ER. A multiple testing correction method for genetic association studies using correlated single nucleotide polymorphisms. Genet Epidemiol [Internet]. 2008 May 1 [cited 2020 Feb 19];32(4):361–9. Available from: http://doi.wiley.com/10.1002/gepi.20310
- 58. Blauw LL, Li-Gao R, Noordam R, de Mutsert R, Trompet S, Berbée JFP, et al. CETP (Cholesteryl
   875 Ester Transfer Protein) Concentration: A Genome-Wide Association Study Followed by
   Mendelian Randomization on Coronary Artery Disease. Circ Genomic Precis Med. 2018
   May;11(5):e002034.
- 59. Consortium the HR, McCarthy S, Das S, Kretzschmar W, Delaneau O, Wood AR, et al. A reference panel of 64,976 haplotypes for genotype imputation. Nat Genet [Internet]. 2016 Oct
  22 [cited 2019 Jan 25];48(10):1279–83. Available from: http://www.nature.com/articles/ng.3643
  - Yengo L, Sidorenko J, Kemper KE, Zheng Z, Wood AR, Weedon MN, et al. Meta-analysis of genome-wide association studies for height and body mass index in approximately 700000 individuals of European ancestry. Hum Mol Genet [Internet]. 2018/08/21. 2018;27(20):3641– 9. Available from: https://www.ncbi.nlm.nih.gov/pubmed/30124842
    - 61. Zeileis A, Hothorn T. Diagnostic Checking in Regression Relationships. R News [Internet]. 2002;2(3):7–10. Available from: https://cran.r-project.org/doc/Rnews/

- 62. Dekkers IA, de Mutsert R, de Vries APJ, Rosendaal FR, Cannegieter SC, Jukema JW, et al. Determinants of impaired renal and vascular function are associated with elevated levels of procoagulant factors in the general population. J Thromb Haemost [Internet]. 2018 Mar 1 [cited 2022 Aug 23];16(3):519–28. Available from: https://onlinelibrary.wiley.com/doi/full/10.1111/jth.13935
  - 63. Nordestgaard BG. A Test in Context: Lipid Profile, Fasting Versus Nonfasting. Vol. 70, Journal of the American College of Cardiology. Elsevier; 2017. p. 1637–46.
- 895 64. Arsenault BJ, Rana JS, Stroes ESG, Després J-P, Shah PK, Kastelein JJP, et al. Beyond low-

density lipoprotein cholesterol: respective contributions of non-high-density lipoprotein cholesterol levels, triglycerides, and the total cholesterol/high-density lipoprotein cholesterol ratio to coronary heart disease risk in apparently healt. J Am Coll Cardiol. 2009 Dec;55(1):35-41.

900 65. Carr SS, Hooper AJ, Sullivan DR, Burnett JR. Non-HDL-cholesterol and apolipoprotein B compared with LDL-cholesterol in atherosclerotic cardiovascular disease risk assessment. Pathology. 2019 Feb;51(2):148-54.

905

- 66. Sniderman AD, Islam S, McQueen M, Pencina M, Furberg CD, Thanassoulis G, et al. Age and Cardiovascular Risk Attributable to Apolipoprotein B, Low-Density Lipoprotein Cholesterol or Non-High-Density Lipoprotein Cholesterol. J Am Heart Assoc. 2016 Oct;5(10).
  - 67. Holmes MV, Lange LA, Palmer T, Lanktree MB, North KE, Almoguera B, et al. Causal Effects of Body Mass Index on Cardiometabolic Traits and Events: A Mendelian Randomization Analysis. Am J Hum Genet [Internet]. 2014;94(2):198–208. Available from: http://www.sciencedirect.com/science/article/pii/S0002929713005843
- 910 68. Arsenault BJ, Després J-P, Stroes ESG, Wareham NJ, Kastelein JJP, Khaw K-T, et al. Lipid assessment, metabolic syndrome and coronary heart disease risk. Eur J Clin Invest. 2010 Dec;40(12):1081-93.
  - 69. Felig P, Marliss E, Cahill GF. Plasma Amino Acid Levels and Insulin Secretion in Obesity. N Engl J Med [Internet]. 1969 Oct 9;281(15):811–6. Available from: http://www.nejm.org/doi/abs/10.1056/NEJM196910092811503
  - 70. Adibi SA. Influence of dietary deprivations on plasma concentration of free amino acids of man. J Appl Physiol. 1968 Jul;25(1):52-7.
  - 71. Luck JM, Morse SW. The effects of insulin and adrenaline on the amino-acid content of blood. Biochem J. 1933;27(5):1648-54.
- 920 72. Floyd JCJ, Fajans SS, Conn JW, Knopf RF, Rull J. Stimulation of insulin secretion by amino acids. J Clin Invest. 1966 Sep;45(9):1487–502.
  - 73. IVY JH, SVEC M, FREEMAN S. Free plasma levels and urinary excretion of eighteen amino acids in normal and diabetic dogs. Am J Physiol. 1951 Oct;167(1):182-92.
- 74. Carlsten A, Hallgren B, Jagenburg R, Svanborg A, Werkö L. Amino acids and free fatty acids in 925 plasma in diabetes. I. The effect of insulin on the arterial levels. Acta Med Scand. 1966 Mar;179(3):361-70.
  - White PJ, Newgard CB. Branched-chain amino acids in disease. Science (80-) [Internet]. 2019 75. Feb 8;363(6427):582-3. Available from: https://www.science.org/doi/10.1126/science.aav0558
- 930 76. Neeland IJ, Boone SC, Mook-Kanamori DO, Ayers C, Smit RAJ, Tzoulaki I, et al. Metabolomics Profiling of Visceral Adipose Tissue: Results From MESA and the NEO Study. J Am Heart Assoc. 2019;8(9).
- 77. Geidenstam N, Al-Majdoub M, Ekman M, Spégel P, Ridderstråle M. Metabolite profiling of obese individuals before and after a one year weight loss program. Int J Obes. 935 2017;41(9):1369-78.
  - 78. Geidenstam N, Danielsson APH, Spégel P, Ridderstråle M. Changes in glucose-elicited blood

metabolite responses following weight loss and long term weight maintenance in obese individuals with impaired glucose tolerance. Diabetes Res Clin Pract. 2016;113:187–97.

- 79. Weng L, Quinlivan E, Gong Y, Beitelshees AL, Shahin MH, Turner ST, et al. Association of
   940 Branched and Aromatic Amino Acids Levels with Metabolic Syndrome and Impaired Fasting
   Glucose in Hypertensive Patients. Metab Syndr Relat Disord [Internet]. 2015 Jun;13(5):195–
   202. Available from: http://www.liebertpub.com/doi/10.1089/met.2014.0132
  - 80. Wang TJ, Larson MG, Vasan RS, Cheng S, Rhee EP, McCabe E, et al. Metabolite profiles and the risk of developing diabetes. Nat Med. 2011;17(4):448–53.
- 945 81. Porcu E, Gilardi F, Darrous L, Yengo L, Bararpour N, Gasser M, et al. Triangulating evidence from longitudinal and Mendelian randomization studies of metabolomic biomarkers for type 2 diabetes. Sci Rep [Internet]. 2021;11(1):1–10. Available from: https://doi.org/10.1038/s41598-021-85684-7
- 82. Lotta LA, Scott RA, Sharp SJ, Burgess S, Luan J, Tillin T, et al. Genetic Predisposition to an Impaired Metabolism of the Branched-Chain Amino Acids and Risk of Type 2 Diabetes: A Mendelian Randomisation Analysis. PLoS Med [Internet]. 2016 Nov 1 [cited 2020 Oct 14];13(11). Available from: https://pubmed.ncbi.nlm.nih.gov/27898682/
- 83. Wang Q, Holmes M V, Davey Smith G, Ala-Korpela M. Genetic Support for a Causal Role of Insulin Resistance on Circulating Branched-Chain Amino Acids and Inflammation. Diabetes
   955 Care [Internet]. 2017 Dec;40(12):1779–86. Available from: http://care.diabetesjournals.org/lookup/doi/10.2337/dc17-1642
  - Fontana L, Cummings NE, Arriola Apelo SI, Neuman JC, Kasza I, Schmidt BA, et al. Decreased
     Consumption of Branched-Chain Amino Acids Improves Metabolic Health. Cell Rep [Internet].
     2016;16(2):520–30. Available from: http://dx.doi.org/10.1016/j.celrep.2016.05.092
- 960 85. Dekkers IA, de Mutsert R, de Vries APJ, Rosendaal FR, Cannegieter SC, Jukema JW, et al. Determinants of impaired renal and vascular function are associated with elevated levels of procoagulant factors in the general population. J Thromb Haemost. 2018 Mar;16(3):519–28.

uon our

## **Tables**

Trait	NEO	Men	Women	Leiderdorp	Leiden	by sub- pop	p-value
sex	M:2671 F:2846	M:2671 F:0	M:0 F:2846	M:623 F:783	M:2048 F:2063	0.17%	3.65E-04
age	55.99 (45.00-65.00)	56.13 (45.00-65.00)	55.86 (45.00-65.00)	56.13 (46.00-65.00)	55.95 (45.00-65.00)	0.02%	3.26E-01
height	1.74 (1.57-1.92)	1.81 (1.68-1.95)	1.67 (1.55-1.79)	1.73 (1.57-1.92)	1.74 (1.57-1.92)	0.03%	2.03E-01
weight	90.58 (60.00- 126.80)	97.45 (72.95-131.60)	84.14 (57.20-121.52)	79.16 (54.00-116.15)	94.49 (69.60-128.85)	16.12%	9.63E-213
waist circ.	102.01 (74.00- 129.00)	106.32 (85.79-131.00)	97.96 (71.00-126.00)	91.22 (70.00-119.00)	105.70 (86.00-131.00)	22.87%	2.85e-313
hip circ.	110.23 (94.00- 133.00)	108.57 (96.00-125.00)	111.79 (92.00-138.00)	103.40 (90.00-124.17)	112.57 (99.00-135.00)	16.22%	3.33E-214
pack years	11.21 (0.00-52.38)	13.71 (0.00-61.69)	8.88 (0.00-43.83)	8.69 (0.00-43.32)	12.09 (0.00-55.20)	0.83%	1.01E-10
alcohol	15.52 (0.00-60.52)	21.40 (0.00-73.24)	10.00 (0.00-41.72)	14.58 (0.00-54.06)	15.84 (0.00-62.57)	0.10%	1.95E-02
smokin g (N F C)	34.11   49.85   16.03	30.32   50.49   19.19	37.67   49.26   13.07	39.29   46.76   13.95	32.34   50.91   16.74	0.38%	4.11E-06
higher ed %	38.58	42.27	35.12	50.5	34.48	1.52%	6.24E-26
BMI	29.98 (21.40-41.35)	29.74 (22.72-38.99)	30.20 (20.64- 42.90)	26.24 (19.94-37.20)	31.26 (26.02-42.19)	20.70%	3.66E-280
BMI- PGS	10.20 (9.64-10.78)	10.20 (9.63-10.78)	10.20 (9.65-10.77)	10.14 (9.56-10.71)	10.22 (9.67-10.80)	1.63%	1.53E-21
R <sup>2</sup>	0.0431, 0.0473**	0.0439	0.0453	0.0427	0.0243	-	-
beta (se)	3.38 (0.21), 3.26 (0.20)**	2.77 (0.25)	4.00 (0.34)	3.14 (0.40)	2.25 (0.22)	-	-
Р	8.10x10 <sup>-55</sup> 3.61x10 <sup>-60**</sup>	7.23x10 <sup>-28</sup>	1.57x10 <sup>-30</sup>	5.10x10 <sup>-15</sup>	8.22x10 <sup>-24</sup>	-	-

#### **Table 1. Population summary statistics**

40

Table 1: Population summary statistics for the (1) complete NEO cohort, for (2) men and (3) women of the NEO cohort and the two NEO sub-populations (4) Leiderdorp and (5) Leiden, respectively. For each variable: age, height, weight, waist circumference, hip circumference, waist-hip ratio, smoking in pack years, alcohol consumption in grams per day, the percent of the population with higher education, BMI, and BMI-PGS the mean (95% confidence intervals) is provided. In addition, the number of men and women in each sample (sub-)population is provided (sex). The last three rows of data provide summary statistics describing the relationship between the instrumental variable (BMI-PGS) on the exposure (BMI). Specifically, the variance explained  $(R^2)$ , the effect estimate (beta) and standard error (se), and the P-value (P) are provided. Estimates suffixed with \*\* are derived from

50 linear models that include sample weights. The last two columns of data provide an estimate of the proportion of variation (in NEO) of the trait (in the row) explained by variation between the subpopulation samples, as estimated by a linear regression, and the model P-value.

45

### Table 2 Metabolite traits causally associated with BMI

trait	metabolite	class	dietary state	beta	se	Р
lafa_f	Ratio of 18:2 linoleic acid to total fatty acids (%)	Fatty acids ratios	fasting	-0.106	0.025	1.80E-05
faw6fa_f	Ratio of omega-6 fatty acids to total fatty acids (%)	Fatty acids ratios	fasting	-0.081	0.024	6.97E-04
pufafa_f	Ratio of polyunsaturated fatty acids to total fatty acids (%)	Fatty acids ratios	fasting	-0.081	0.024	6.80E-04
cit_f	Citrate (mmol/l)	Glycolysis related metabolites	fasting	-0.079	0.024	8.63E-04
leu_f	Leucine (mmol/l)	Amino acids	fasting	0.068	0.020	5.62E-04
lhdlc_p	Total cholesterol in large HDL (mmol/l)	Lipoprotein subclasses	postprandial	-0.076	0.023	1.12E-03
lhdlfc_p	Free cholesterol in large HDL (mmol/l)	Lipoprotein subclasses	postprandial	-0.077	0.023	9.73E-04
mvldlplpct_p	Phospholipids in medium VLDL to total lipids in medium VLDL ratio (%)	Lipoprotein subclasses ratios	postprandial	-0.073	0.022	9.98E-04
idlfcpct_p	Free cholesterol in IDL to total lipids in IDL ratio (%)	Lipoprotein subclasses ratios	postprandial	-0.079	0.023	5.08E-04
lhdlcpct_p	Total cholesterol in large HDL to total lipids in large HDL ratio (%)	Lipoprotein subclasses ratios	postprandial	-0.085	0.025	7.90E-04
lhdlcepct_p	Cholesterol esters in large HDL to total lipids in large HDL ratio (%)	Lipoprotein subclasses ratios	postprandial	-0.086	0.026	1.03E-03
lhdlfcpct_p	Free cholesterol in large HDL to total lipids in large HDL ratio (%)	Lipoprotein subclasses ratios	postprandial	-0.095	0.025	1.20E-04
lafa_p	Ratio of 18:2 linoleic acid to total fatty acids (%)	Fatty acids ratios	postprandial	-0.092	0.025	2.00E-04
faw6fa_p	Ratio of omega-6 fatty acids to total fatty acids (%)	Fatty acids ratios	postprandial	-0.080	0.024	7.83E-04
pufafa_p	Ratio of polyunsaturated fatty acids to total fatty acids (%)	Fatty acids ratios	postprandial	-0.077	0.024	1.10E-03
cit_p	Citrate (mmol/l)	Glycolysis related metabolites	postprandial	-0.105	0.022	2.83E-06

medRxiv preprint doi: https://doi.org/10.1101/2023.08.21.23294369; this version posted August 22, 2023. The copyright holder for this preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.

his_p	Histidine (mmol/l)	Amino acids	postprandial	-0.085	0.024	3.96E-04
mvldlplpct_r	Phospholipids in medium VLDL to total lipids in medium VLDL ratio (%)	Lipoprotein subclasses ratios	response	-0.091	0.027	6.75E-04
svldlfcpct_r	Free cholesterol in small VLDL to total lipids in small VLDL ratio (%)	Lipoprotein subclasses ratios	response	-0.082	0.025	1.11E-03
ala_r	Alanine (mmol/l)	Amino acids	response	-0.081	0.023	5.91E-04

**Table 2:** MR association summary statistics for the 20 metabolite traits associated with BMI. Provided are the trait name, metabolite description and units, metabolite class as defined by Nightingale Heath, the dietary state, and the effect estimate, standard error, and P-value. The effect estimates are in normalized standard deviation units of change per 1 unit change of BMI (kg/m<sup>2</sup>).

### **Figures**

#### **Figure 1 Mendelian Randomization schematic**





Figure 1: A schematic or directed acyclic graph of the Mendelian randomization framework. The MR framework in this study assumes (1) that the instrument is robustly associated with the outcome, (2) that the instrument is not associated with variables that are associated to the outcome and (3) that

70 the instrument acts on the outcome only through the exposure and not through a pleiotropic pathway.



### Figure 2: Observational effect estimate forest plot

Figure 2: Observational BMI – metabolite abundance and response effect estimates. Point estimates and 95% confidence intervals for BMI on fasting metabolite abundance (green),

80 postprandial metabolite abundance (blue), and metabolite response (red). Metabolites are classified and organized by Nightingale Health sub-class assignments. Metabolites that are associated with BMI, after multiple test correction (P<0.05/43), are indicated as solid color point estimates.

#### **Figure 3: Scatter plots** 85



90

is an equivalency line (intercept = 0, slope = 1), the dashed vertical and horizontal line indicate the zero values, and a Pearson's correlation coefficient is in the bottom right corner. (A) Scatter plot of BMI-metabolite cross-sectional effect estimates for females (x-axis) and males (y-axis). Point estimates are colored red if there is an association between the metabolite and BMI in both sexes, blue if an association was only observed in females, green if an association was only observed in males, and purple if no association was observed in either sex. Point estimates are shaped as circles,

Figure 3: Scatter plots. In all plots the solid black line is a best fit regression line, the dotted black line

95 respectively. (B) Scatter plot of BMI-metabolite cross-sectional effect estimates from Wurtz et al (xaxis) and NEO (this study, y-axis). Point estimates are colored red if there is an association between the metabolite and BMI in NEO, blue if an association was only observed in Wurtz et al, green if an association was observed in both studies, and purple if no association was observed in either study. (C) Scatter plot of BMI-metabolite cross-sectional effect estimates for fasting (x-axis) and

squares, and triangles to represent the three dietary states fasting, postprandial, and response,

100 postprandial (y-axis) dietary states. Point estimates are colored red if there is an association between

the metabolite and BMI in the fasting state, blue if an association was only observed in the postprandial state, green an association was observed in both dietary states, and purple if no association was observed in either. Point estimates are shaped as circles if they are not different between the two dietary states – as determined by a z-test – shaped as squares if they are nominally different (P < 0.05) and triangles and labeled if they are different after correcting for multiple tests (P < 0.05/229). (D) Scatter plot of BMI-metabolite cross-sectional (x-axis) and MR (y-axis) effect in the fasting (top and green), postprandial (middle and blue), and response (bottom and red) dietary states. Metabolites with effect estimates that differ between the cross-sectional and MR analyses are solid circles and labelled with the metabolite name.

#### 110

115

105



#### **Figure 4 Alanine response**

Figure 4: Association of BMI with alanine response. Plot on the left illustrates the correlation between fasting (x-axis) and postprandial (y-axis) tyrosine abundance, with a best fit line for 4 BMI classes of individuals: healthy (BMI < 25), overweight (25 <= BMI < 30), obese (30 <= BMI < 40), and severely obese (BMI > 40). All best fit lines were forced through an intercept of zero. Note that the slope of the best fit line is largest for individuals who have a healthy BMI and smallest for those who

have severe obesity. The plot on the right illustrates the inverse relationship between BMI (x-axis) and tyrosine response (y-axis). The blue line is a best fit linear regression line, the black line is a best

120 fit generalized additive model (GAM) smooth (non-linear regression), and the red, blue, green, and purple line intervals are best fit regression for each clinically defined portion of the BMI distribution, which mirror the non-linear regression.

#### Figure 5: Forest plot of MR effect estimates 125



Figure 5: Forest Plot of MR effect estimates. Point estimates and 95% confidence intervals for BMI on fasting metabolite abundance (green), postprandial metabolite abundance (blue), and metabolite response (red). Metabolites are classified and organized by Nightingale Health sub-class assignments. Metabolites that are associated with BMI, after multiple test correction (P<0.05/43), are indicated as solid color point estimates.

#### 135

140



### Figure 6: Metabolites associated with BMI in MR analyses

Figure 6: Metabolites associated with BMI in MR analyses. A forest plot of effect estimates (points) and 95% confidence intervals (whiskers) for MR (blue, "tsls" prefix) and observational (green, "obs" prefix) effect estimates for the weighted NEO (wNEO), weighted NEO female (wNEO female), and weighted NEO male (wNEO\_male) (sub-)populations. Fasting, postprandial, and response association observed in the general population as well as those association only seen in females and males.



## Figure 7: Fasting lipoprotein cross-sectional profile

145

Figure 7: Fasting lipoprotein cross-sectional profile. (Upper) A tile plot of cross-sectional effect estimates for lipoproteins and lipoprotein ratios in the fasting state. Tiles with an effect estimate provided in text are those associated with BMI ( $p<1.16x10^{-3}$ ). The lipoproteins are organized by size or density along the x-axis, and the component or ratio being measured is along the y-axis. (Lower) A dot plot or profile of cross-sectional effect estimates for lipoproteins (x-axis) ordered by lipoprotein size or density with effect estimates (y-axis). The component or measurement of each lipoprotein are

150

defined by the color as described in the key.